Skip to main content
. Author manuscript; available in PMC: 2017 Oct 28.
Published in final edited form as: J Control Release. 2015 Oct 28;240:2–8. doi: 10.1016/j.jconrel.2015.10.048

Table 1.

Barriers to overcome by the 3G DDSs. (From reference [31]).

1. Delivery of poorly soluble drugs
 Non-toxic excipients
2. Peptide/protein/nucleic acid delivery
 Control of the initial burst release and subsequent release rate
 Non-invasive delivery
In vitro-in vivo correlation
3. Targeted drug delivery
 Tumor targeting in human
 Overcoming blood-brain barrier
4. Self-regulated drug delivery
 Functional in the body for extended period of time